| Name | Title | Contact Details |
|---|
Nautilus, Inc. is an iconic industry leader with a rich history and reputation as an innovative company building the best cardio and strength equipment for home use. Known for its family of brands that includes Bowflex®, Nautilus®, and Schwinn® Fitness, Nautilus, Inc. develops, manufacturers and markets branded products that include strength, cardio and fitness accessories through direct and retail channels. With its headquarters and innovation center located in Vancouver, Washington, Nautilus, Inc. employs nearly 500 employees and has offices in Brooklyn Park, Minnesota and Shanghai, China, as well as distribution centers in Portland, Oregon, Columbus, Ohio, and Rotterdam, The Netherlands.
Lifebank Inc is a Cedar Knolls, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dental Art Laboratory Inc is a Lansing, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Margaret's Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Spring Valley, IL. To find more information about St. Margaret's Hospital, please visit www.aboutsmh.org
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.